Treatment with PLGA-PEG-B6/Cur was led to a decrement in the level of Aß and tau phosphorylation and inhibited the generation of BACE1, APP, and PS1as markers of Alzheimer’s disease. Here, MAPT is linked to Alzheimer disease.